HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise against tough head and neck cancer
Disease control CompletedThis study tested a new drug (MK-1454) injected directly into tumors, combined with the immunotherapy pembrolizumab, for people with advanced head and neck cancer that cannot be removed by surgery. The goal was to see if the combination worked better than pembrolizumab alone. The…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug duo shows promise in early cancer trial
Disease control CompletedThis early-phase study tested a new antibody (BGB-A445) alone or with another drug (tislelizumab) in 204 people with advanced solid tumors, including lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. While the treatment a…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Less time under the beam: shorter radiation may ease burden for seniors with head and neck cancer
Symptom relief CompletedThis study tested a shorter course of radiation therapy for people aged 70 and older with head and neck cancer. The goal was to see if fewer treatments could reduce side effects and help patients finish their therapy. 37 participants received radiation over a shorter period than …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated May 17, 2026 05:34 UTC